company background image
F6T logo

Fate Therapeutics DB:F6T Stock Report

Last Price

€2.21

Market Cap

€254.4m

7D

-9.7%

1Y

0.8%

Updated

04 Nov, 2024

Data

Company Financials +

Fate Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Fate Therapeutics
Historical stock prices
Current Share PriceUS$2.21
52 Week HighUS$7.59
52 Week LowUS$1.85
Beta1.84
11 Month Change-21.44%
3 Month Change-41.98%
1 Year Change0.78%
33 Year Change-95.86%
5 Year Change-83.13%
Change since IPO-56.38%

Recent News & Updates

Recent updates

Shareholder Returns

F6TDE BiotechsDE Market
7D-9.7%0.8%-2.2%
1Y0.8%-14.4%13.3%

Return vs Industry: F6T exceeded the German Biotechs industry which returned -15.4% over the past year.

Return vs Market: F6T underperformed the German Market which returned 13.6% over the past year.

Price Volatility

Is F6T's price volatile compared to industry and market?
F6T volatility
F6T Average Weekly Movement9.6%
Biotechs Industry Average Movement6.1%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.2%
10% least volatile stocks in DE Market2.4%

Stable Share Price: F6T's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: F6T's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
2007181J. Wolchkowww.fatetherapeutics.com

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company’s chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors.

Fate Therapeutics, Inc. Fundamentals Summary

How do Fate Therapeutics's earnings and revenue compare to its market cap?
F6T fundamental statistics
Market cap€254.42m
Earnings (TTM)-€161.56m
Revenue (TTM)€11.32m

25.5x

P/S Ratio

-1.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
F6T income statement (TTM)
RevenueUS$12.32m
Cost of RevenueUS$121.93m
Gross Profit-US$109.62m
Other ExpensesUS$66.11m
Earnings-US$175.72m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.54
Gross Margin-889.96%
Net Profit Margin-1,426.67%
Debt/Equity Ratio0%

How did F6T perform over the long term?

See historical performance and comparison